Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes

JF. Seymour, M. Pfreundschuh, M. Trnĕný, LH. Sehn, J. Catalano, E. Csinady, N. Moore, B. Coiffier, . ,

. 2014 ; 99 (8) : 1343-9.

Jazyk angličtina Země Itálie

Typ dokumentu srovnávací studie, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc15023352

Vascular endothelial growth factor is involved in lymphoma growth, suggesting a potential role for anti-vascular endothelial growth factor therapies in hematologic malignancies. In this phase III study, patients with CD20-positive diffuse large B-cell lymphoma were randomized to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone plus either placebo (R-CHOP) or bevacizumab (RA-CHOP). Treatment was administered every 21 (8 cycles) or 14 days (6 cycles plus 2 rituximab cycles) as per institutional practice. An early analysis of risk/benefit by the Data and Safety Monitoring Board showed that RA-CHOP increased cardiotoxicity without prolonging progression-free survival compared with R-CHOP, and the trial was stopped early. The study protocol was amended to allow for 12 additional months of follow up to evaluate safety. With 787 patients enrolled, median follow up was 23.7 and 23.6 months for R-CHOP and RA-CHOP, respectively. Median progression-free survival for R-CHOP and RA CHOP was 42.9 and 40.2 months, respectively (hazard ratio=1.09; P=0.49). The proportion of deaths was identical for R-CHOP (83 of 387, 21%) and RA-CHOP (82 of 390, 21%). Relative to R-CHOP, RA-CHOP had a higher rate of left ventricular ejection fraction perturbation (18% vs. 8%; odds ratio=2.51; 95% confidence interval (CI): 1.60-3.93) and congestive heart failure (16% vs. 7%; odds ratio=2.79; 95%CI: 1.72-4.54). Bevacizumab added to R-CHOP increased cardiac events, without increasing efficacy, arguing against further evaluation of RA-CHOP in patients with diffuse large B-cell lymphoma. The MAIN study is registered at clinicaltrials.gov identifier:00486759.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023352
003      
CZ-PrNML
005      
20240313102905.0
007      
ta
008      
150709s2014 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2013.100818 $2 doi
035    __
$a (PubMed)24895339
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Seymour, John F $u Peter MacCallum Cancer Centre, East Melbourne, Australia University of Melbourne, Parkville, Australia John.Seymour@petermac.org.
245    10
$a R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes / $c JF. Seymour, M. Pfreundschuh, M. Trnĕný, LH. Sehn, J. Catalano, E. Csinady, N. Moore, B. Coiffier, . ,
520    9_
$a Vascular endothelial growth factor is involved in lymphoma growth, suggesting a potential role for anti-vascular endothelial growth factor therapies in hematologic malignancies. In this phase III study, patients with CD20-positive diffuse large B-cell lymphoma were randomized to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone plus either placebo (R-CHOP) or bevacizumab (RA-CHOP). Treatment was administered every 21 (8 cycles) or 14 days (6 cycles plus 2 rituximab cycles) as per institutional practice. An early analysis of risk/benefit by the Data and Safety Monitoring Board showed that RA-CHOP increased cardiotoxicity without prolonging progression-free survival compared with R-CHOP, and the trial was stopped early. The study protocol was amended to allow for 12 additional months of follow up to evaluate safety. With 787 patients enrolled, median follow up was 23.7 and 23.6 months for R-CHOP and RA-CHOP, respectively. Median progression-free survival for R-CHOP and RA CHOP was 42.9 and 40.2 months, respectively (hazard ratio=1.09; P=0.49). The proportion of deaths was identical for R-CHOP (83 of 387, 21%) and RA-CHOP (82 of 390, 21%). Relative to R-CHOP, RA-CHOP had a higher rate of left ventricular ejection fraction perturbation (18% vs. 8%; odds ratio=2.51; 95% confidence interval (CI): 1.60-3.93) and congestive heart failure (16% vs. 7%; odds ratio=2.79; 95%CI: 1.72-4.54). Bevacizumab added to R-CHOP increased cardiac events, without increasing efficacy, arguing against further evaluation of RA-CHOP in patients with diffuse large B-cell lymphoma. The MAIN study is registered at clinicaltrials.gov identifier:00486759.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a inhibitory angiogeneze $x aplikace a dávkování $7 D020533
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $7 D061067
650    _2
$a myší monoklonální protilátky $x aplikace a dávkování $7 D058846
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    _2
$a doxorubicin $x aplikace a dávkování $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a difúzní velkobuněčný B-lymfom $x diagnóza $x farmakoterapie $7 D016403
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prednison $x aplikace a dávkování $7 D011241
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vinkristin $x aplikace a dávkování $7 D014750
650    _2
$a mladý dospělý $7 D055815
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Pfreundschuh, Michael $u Saarland University Hospital, Homburg, Germany.
700    1_
$a Trnĕný, Marek $u General Hospital, Charles University First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Sehn, Laurie H $u Centre for Lymphoid Cancer, British Columbia Cancer Agency, Canada.
700    1_
$a Catalano, John $u Frankston Hospital and Monash University, Frankston, Australia.
700    1_
$a Csinady, Eva $u F. Hoffmann-La Roche Ltd. Pharmaceuticals Division, PDCO, Basel, Switzerland.
700    1_
$a Moore, Nicola $u F. Hoffmann-La Roche Ltd. Pharmaceuticals, Biostatistics, Basel, Switzerland.
700    1_
$a Coiffier, Bertrand, $d 1947-2019 $u Centre Hospitalier Lyon-Sud, Lyon, France. $7 xx0314848
700    1_
$a ,
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 99, č. 8 (2014), s. 1343-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24895339 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20240313102900 $b ABA008
999    __
$a ok $b bmc $g 1083690 $s 906345
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 99 $c 8 $d 1343-9 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20150709

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace